These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 23981262)

  • 41. Reducing obesity and related chronic disease risk in children and youth: a synthesis of evidence with 'best practice' recommendations.
    Flynn MA; McNeil DA; Maloff B; Mutasingwa D; Wu M; Ford C; Tough SC
    Obes Rev; 2006 Feb; 7 Suppl 1():7-66. PubMed ID: 16371076
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Epidemiologic studies of adverse effects of anti-retroviral drugs: how well is statistical power reported.
    Halpern SD; Barton TD; Gross R; Hennessy S; Berlin JA; Strom BL
    Pharmacoepidemiol Drug Saf; 2005 Mar; 14(3):155-61. PubMed ID: 15624138
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Interpretation of associations in pharmacoepidemiology.
    Kaufman DW
    Semin Hematol; 2008 Jul; 45(3):181-8. PubMed ID: 18582625
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Active drug safety surveillance: a tool to improve public health.
    Platt R; Madre L; Reynolds R; Tilson H
    Pharmacoepidemiol Drug Saf; 2008 Dec; 17(12):1175-82. PubMed ID: 18823068
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacogenetics and pharmacoepidemiology.
    Jones JK
    Pharmacoepidemiol Drug Saf; 2001; 10(5):457-61. PubMed ID: 11802592
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Using propensity scores subclassification to estimate effects of longitudinal treatments: an example using a new diabetes medication.
    Segal JB; Griswold M; Achy-Brou A; Herbert R; Bass EB; Dy SM; Millman AE; Wu AW; Frangakis CE
    Med Care; 2007 Oct; 45(10 Supl 2):S149-57. PubMed ID: 17909374
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recommendations for benefit-risk assessment methodologies and visual representations.
    Hughes D; Waddingham E; Mt-Isa S; Goginsky A; Chan E; Downey GF; Hallgreen CE; Hockley KS; Juhaeri J; Lieftucht A; Metcalf MA; Noel RA; Phillips LD; Ashby D; Micaleff A;
    Pharmacoepidemiol Drug Saf; 2016 Mar; 25(3):251-62. PubMed ID: 26800458
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Pharmacoepidemiology of antiepileptic drugs in children: comparative analysis of drug effectiveness and safety].
    Gamirova RG; Ziganshina LE
    Eksp Klin Farmakol; 2008; 71(6):3-7. PubMed ID: 19140506
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Case-only designs in pharmacoepidemiology: a systematic review.
    Nordmann S; Biard L; Ravaud P; Esposito-Farèse M; Tubach F
    PLoS One; 2012; 7(11):e49444. PubMed ID: 23166668
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Case-crossover study design in pharmacoepidemiology: systematic review and recommendations.
    Consiglio GP; Burden AM; Maclure M; McCarthy L; Cadarette SM
    Pharmacoepidemiol Drug Saf; 2013 Nov; 22(11):1146-53. PubMed ID: 24030723
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacoepidemiology research: delivering evidence about drug safety and effectiveness in mental health.
    Davis KAS; Farooq S; Hayes JF; John A; Lee W; MacCabe JH; McIntosh A; Osborn DPJ; Stewart RJ; Woelbert E
    Lancet Psychiatry; 2020 Apr; 7(4):363-370. PubMed ID: 31780306
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Orthogonal predictions: follow-up questions for suggestive data.
    Walker AM
    Pharmacoepidemiol Drug Saf; 2010 May; 19(5):529-32. PubMed ID: 20309840
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Using secondary data sources for pharmacoepidemiology and outcomes research.
    Harpe SE
    Pharmacotherapy; 2009 Feb; 29(2):138-53. PubMed ID: 19170584
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Benefit-Risk Assessment, Communication, and Evaluation (BRACE) throughout the life cycle of therapeutic products: overall perspective and role of the pharmacoepidemiologist.
    Radawski C; Morrato E; Hornbuckle K; Bahri P; Smith M; Juhaeri J; Mol P; Levitan B; Huang HY; Coplan P; Li H;
    Pharmacoepidemiol Drug Saf; 2015 Dec; 24(12):1233-40. PubMed ID: 26456379
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Role of pharmacoepidemiology in evaluating prescription drug safety in pediatrics.
    Luo X; Doherty J; Cappelleri JC; Frush K
    Curr Med Res Opin; 2007 Nov; 23(11):2607-15. PubMed ID: 17854515
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM
    Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
    [TBL] [Abstract][Full Text] [Related]  

  • 58. What can we really learn from observational studies?: the need for empirical assessment of methodology for active drug safety surveillance and comparative effectiveness research.
    Madigan D; Ryan P
    Epidemiology; 2011 Sep; 22(5):629-31. PubMed ID: 21811110
    [No Abstract]   [Full Text] [Related]  

  • 59. Pharmacoepidemiology and gastroenterology: a close couple.
    Leufkens HG
    Scand J Gastroenterol Suppl; 2000; (232):105-8. PubMed ID: 11232486
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Posttraumatic stress disorder (PTSD) as a consequence of the interaction between an individual genetic susceptibility, a traumatogenic event and a social context].
    Auxéméry Y
    Encephale; 2012 Oct; 38(5):373-80. PubMed ID: 23062450
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.